Ipoh Community Forums

Full Version: Quercetin supplementation may reduce COVID-19 severity
You're currently viewing a stripped down version of our content. View the full version with proper formatting.
[Image: F_112278.jpeg]

Quercetin Phytosome supplementation, in combination with standard care, may improve the early symptoms of COVID-19 and help mitigate the infection’s severity. It also statistically shortens the timing of molecular test conversion from positive to negative. These are the results of two recently issued human studies1 based on data produced in the last 15 months for Indena’s Quercefit.

The company stresses it’s critical to follow local and international guidelines, and that individuals should contact a health professional if they experience any symptoms associated with COVID-19. It also advocates, however, that some botanical ingredients, including quercetin, can help modulate immune and inflammatory responses in those suffering from respiratory conditions.

“Starting from the mentioned evidences, we carried out a first prospective, randomised, controlled, and open-label study, in which in addition to standard care a daily dose of 1000 mg of quercetin Phytosome was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease,” said Prof Ikram Ujjan, MBBS, Pro Vice Chancellor, Liaquat University of Medical and Health Sciences (LUMHS). “According to the results of this clinical research, the add-on therapy with quercetin Phytosome has significantly reduced the need (68.2%) and the length (76.8%) of hospitalisation, the need of non-invasive oxygen therapy (93.3%), the progression to intensive care units (none versus 8 subjects) and the number of deaths (none versus 3 subjects). Globally considered, using quercetin Phytosome as add-on therapy to standard care has reduced by 91.6% the days of hospitalisation”.

- More -